Biocair, a global leader in GDP logistics for the pharmaceutical, biotechnology and life sciences sectors, is proud to announce its partnership with Aramex Ireland to expand its presence in the Irish market.
With Biocair's focus on providing the most comprehensive time-sensitive and temperature-controlled logistics services available, and Aramex Ireland’s operations and facilities to deliver life science goods, the partnership is poised to grow an established presence in Ireland for the life science market.
Through this partnership, Biocair and Aramex Ireland will offer a fully…
The companies are working together on next-generation technology in the fast-growing field of synthetic biology. This new technology will improve the quality, speed, and cost of developing synthetic biological solutions such as life-saving vaccines, medicines, treatments, and therapies.
Cambridge, UK, 06 December 2023 – EVONETIX LTD (‘Evonetix’), the company developing semiconductor scale technology to improve access to gene synthesis, today announces the signing of a joint development agreement and commercial supply agreement with Analog Devices, Inc. (ADI), a global semiconductor leader.…
BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures
BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December
Sandwich, UK, 6th December 2023 / Sciad Newswire / Discovery Park / BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £…
ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.
Ambrose Healthcare is seeking to develop new treatments for rare diseases and patients managed in hospitals and specialist care. The company, incorporated in 2022, has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry.
VAL401 is the reformulation of the established…
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822
Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease
Cambridge, UK, 4 December 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced its PhysioMimix…
Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.
DPV was formed in 2022 by Discovery Park to invest in promising, fast-growing life-science companies with close links to the innovation ecosystem at Discovery Park…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
Cambridge, UK, 4 December 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products…
Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Judit Molnar, a seasoned pharmaceutical physician and leader, with experience across large pharma and biotech. as a Non-Executive Director. Judit is VP and Head of Early Development, tranScrip, leading the Early Development Team, supporting clients with early development activities from pre-clinical stage…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR CONTINUES COLLABORATION WITH LILLY
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).
Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a…
Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.
NanoString GeoMx DSP is a new flexible multi-omics platform that enables reliable quantitative assessment of the spatial heterogeneity within various sample types including FFPE, TMAs, and fresh-frozen tissue - with no prequalification required. Tackling the challenge of compromised sample data due to non-target tissue cells, NanoString GeoMx DSP integrates cutting-edge in situ visualization with molecular…